Skip to navigation menu Skip to content
Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature

BMN-111-210 Vosoritide

  • Condition(s): Other
  • Phase: II
  • Clinicaltrials.gov ID: NCT06382155

What is the goal of the study?

Study 111-210 is a Phase 2, randomized, multicenter study of vosoritide in children with Idiopathic Short Stature (ISS) who are naïve to growth hormone treatment, intended to characterize the short-term efficacy and safety of 3 dosing regimens of vosoritide in reference to placebo in a blinded setting (in the Dose-Finding Phase), and to provide a long-term efficacy and safety assessment of the therapeutic dose of vosoritide versus human growth hormone (hGH) in an open-label setting (in the Long-Term Phase).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: